Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL HIGHLIGHTS

For the six months ended June 30, 2026:

- Revenue was US$171.4 million, representing an increase of 3.6% compared with the same period of 2025.
- Revenue from International markets (excluding North America) was US$127.0 million, representing an increase of 16.7% compared with the same period of 2025.
- Revenue from Injectables was US$22.2 million, representing an increase of 54.2% compared with the same period of 2025.
- Revenue from Medical Aesthetics (excluding North America) was US$97.1 million, representing an increase of 7.2% YoY.
- Gross profit margin was 56.7%, compared with 60.0% in the same period of 2025.
- Adjusted net profit was US$5.0 million, compared with US$12.0 million in the same period of 2025.

INTERIM DIVIDEND

- The Board resolved not to declare any interim dividend for the six months ended June 30, 2026.

RESULTS HIGHLIGHTS

The board of directors (the "**Board**") of Sisram Medical Ltd (the "**Company**" or "**Sisram**") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively referred to as the "**Group**" or "**we**") for the six months ended June 30, 2026 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2025. The results have been prepared in accordance with International Financial Reporting Standards (the "**IFRSs**").

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS
For the six months ended June 30, 2026

	Notes	For the six months ended June 30, 2026 *(Unaudited) US$'000*	2025 *(Unaudited) US$'000*
REVENUE	4	171,423	165,476
Cost of sales		(74,204)	(66,129)
Gross profit		97,219	99,347
Other income and gains	4	1,854	4,634
Selling and distribution expenses		(67,863)	(63,224)
Administrative expenses		(18,751)	(17,015)
Research and development expenses		(6,685)	(8,055)
Other expenses		(1,436)	(2,346)
Finance costs	5	(2,003)	(1,432)
Share of profits and losses of associates		(77)	(118)
PROFIT BEFORE TAX	6	2,258	11,791
Income tax expense	7	(1,205)	(2,804)
PROFIT FOR THE PERIOD		1,053	8,987
Attributable to:			
Owners of the parent		(1,155)	6,426
Non-controlling interests		2,208	2,561
		1,053	8,987
(LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	9		
Basic and diluted			
— For (loss)/profit for the period (US cents)		(0.25)	1.37

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the six months ended June 30, 2026

	For the six months ended June 30,	
	2026	**2025**
	(Unaudited)	*(Unaudited)*
	US$'000	*US$'000*
PROFIT FOR THE PERIOD	1,053	8,987
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Cash flow hedges:		
Effective portion of changes in fair value of hedging instruments arising during the period	820	1,362
Reclassification adjustments for gain included in the consolidated statement of profit or loss	(1,328)	(289)
	(508)	1,073
Exchange differences:		
Exchange differences on translation of foreign operations	2,704	2,121
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods	2,196	3,194
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	2,196	3,194
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	3,249	12,181
Attributable to:		
Owners of the parent	649	9,894
Non-controlling interests	2,600	2,287
	3,249	12,181

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
June 30, 2026

	Notes	June 30, 2026 *(Unaudited)* *US$'000*	December 31, 2025 *(Audited)* *US$'000*
NON-CURRENT ASSETS			
Property, plant and equipment	10	20,520	21,318
Right-of-use assets		34,242	35,471
Goodwill		126,915	126,915
Other intangible assets		133,245	136,695
Deferred tax assets		11,381	9,950
Trade receivables	11	32,138	35,918
Investments in associates		7,443	7,297
Financial assets at fair value through profit or loss		2,918	2,827
Other non-current assets		8,325	4,574
Total non-current assets		377,127	380,965
CURRENT ASSETS			
Inventories		97,299	93,289
Trade receivables	11	104,920	92,587
Prepayments, other receivables and other assets		19,210	18,714
Derivative financial instruments		209	728
Cash and bank balances		77,268	70,973
Total current assets		298,906	276,291
CURRENT LIABILITIES			
Contract liabilities		9,169	12,036
Trade payables	12	24,499	22,927
Other payables and accruals		45,703	50,300
Interest-bearing bank and other borrowings		36,113	10,788
Lease liabilities		6,199	5,501
Tax payables		4,515	4,701
Total current liabilities		126,198	106,253

	Notes	June 30, 2026 (Unaudited) US$'000	December 31, 2025 (Audited) US$'000
NET CURRENT ASSETS		172,708	170,038
TOTAL ASSETS LESS CURRENT LIABILITIES		549,835	551,003
NON-CURRENT LIABILITIES			
Contract liabilities		4,827	3,458
Lease liabilities		36,555	35,464
Deferred tax liabilities		5,926	7,211
Other long-term liabilities		1,302	1,189
Total non-current liabilities		48,610	47,322
NET ASSETS		501,225	503,681
EQUITY			
Equity attributable to owners of the parent			
Share capital		1,334	1,334
Reserves		473,462	478,518
		474,796	479,852
Non-controlling interests		26,429	23,829
Total equity		501,225	503,681

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended June 30, 2026 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's (Sisram Medical Ltd (the "**Company**") and its subsidiaries, collectively the "**Group**") consolidated financial statements as at December 31, 2025.

2. CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period's financial information.

Amendments to IFRS 9 and IFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*
Annual Improvements to IFRS Accounting Standards — Volume 11	*Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7*

The nature and impact of the amended IFRS Accounting Standards are described below:

(a) Amendments to IFRS 9 and IFRS 7 Amendments to the *Classification and Measurement of Financial Instruments* clarify that a financial asset is derecognized when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognized on the settlement date. The amendments introduce an accounting policy option to derecognize a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.

(b) *Annual Improvements to IFRS Accounting Standards* — Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying *Guidance on implementing IFRS 7*), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group's operating activities are related to a single operating segment, which is the design, development, manufacture and sale of energy-based aesthetic medical and minimally invasive treatment devices, non-energy-based devices ("**non-EBD**"), injectables and cosmeceuticals. Therefore, no analysis by operating segment is presented.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Revenue from contracts with customers	171,423	165,476

Disaggregated revenue information for revenue from contracts with customers

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Types of goods or services		
Sale of goods	159,737	156,467
Provision of services	11,686	9,009
Total	171,423	165,476

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Geographical information		
Asia Pacific	78,407	65,825
North America	44,389	56,597
Europe	26,708	23,827
Middle East and Africa	16,817	13,910
Latin America	5,102	5,317
Total	171,423	165,476

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Timing of revenue recognition		
Goods transferred at a point in time	159,737	156,467
Services transferred at a point in time	3,086	—
Services transferred over time	8,600	9,009
Total	171,423	165,476

Other income and gains

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Bank interest income	121	263
Foreign exchange gain, net	(101)	3,573
Others	1,834	798
Total	1,854	4,634

5. FINANCE COSTS

An analysis of finance costs is as follows:

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Interest on loans and borrowings	733	203
Interest on lease liabilities	1,270	1,229
Total	2,003	1,432

6. PROFIT BEFORE TAX

The Group's profit before tax from continuing operations is arrived at after charging:

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Cost of inventories sold	69,961	61,332
Cost of services and others	4,243	4,797
	74,204	66,129
Research and development costs:		
Current period expenditure	6,685	8,055
Depreciation of property, plant and equipment	1,619	1,710
Depreciation of right-of-use assets	3,021	3,069
Amortization of other intangible assets	6,290	3,825
Provision for impairment of inventories	586	1,826
Provision for impairment of trade receivables	378	309
Share of profits and losses of associates	77	118
Foreign exchange (loss)/gain, net	101	(3,573)

7. INCOME TAX

Israel

The Israeli corporate tax rate applicable to the Company was 23% for the reporting period (2025: 23%). Each entity in the Group is taxable based on its standalone results as measured by the local tax system.

Alma Lasers Ltd. ("**Alma**"), a major operating subsidiary of the Company, was granted the status of "Preferred Enterprise" under the Law for the Encouragement of Capital Investments, 1959 (as amended in 2011, the "**2011 Amendment of the Investment Law**") and therefore enjoyed a preferential corporate tax rate of 16% during the period.

For a Special Preferred Technological Enterprise ("**SPTE**") where the parent company's total revenues are more than NIS10 billion in the tax year, its preferred technological income will be subject to a tax rate of 6%, regardless of its geographical location.

As of June 30, 2026, Alma enjoyed a preferential effective tax rate of 6% for being a SPTE for the period ended June 30, 2026 (2025: 6%).

United States

The subsidiary operating in the United States is subject to the United States federal and multiple state income tax. The United States federal income tax was provided at the rate of 21% during the year, and multiple state income tax was provided at the average rate of 6% during the year on the estimated assessable profits arising in the United States.

Chinese mainland

The income of Sisram Medical (Tianjin) Ltd., Shanghai Foshion Medical System Co., Ltd., Xingyuanda Medical Technology Huaian Co., Ltd. and Alma Feidun Technology (Chengdu) Co., Ltd., subsidiaries established in the PRC, are taxed at the rate of 25%.

Other overseas subsidiaries

Taxes on taxable income assessable elsewhere have been calculated at the rates of tax prevailing in the countries in which the Group operates.

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
Current	3,921	2,847
Deferred	(2,716)	(43)
Total tax charge for the period	1,205	2,804

8. DIVIDENDS

The board of directors resolved not to declare any interim dividend for the reporting period (six months ended 30 June 2025: Nil).

On March 23, 2026, the board of directors resolved to declare a final dividend of HK$0.095 (inclusive of tax) per share for the year ended December 31, 2025. No dividends were paid during the period ended June 30, 2026 (six months ended June 30, 2025: Nil).

9. (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings/(loss) per share amount is based on the profit/(loss) for the six months ended June 30, 2026 and 2025 attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 468,343,092 (six months ended June 30, 2025: 468,343,092) outstanding during the period.

The Group had no potentially dilutive ordinary shares in issue during the period ended 30 June 2025 and 2026.

The calculation of basic earnings/(loss) per share is based on:

	For the six months ended June 30,	
	2026	**2025**
	US$'000	*US$'000*
	(Unaudited)	*(Unaudited)*
(Loss)/Earnings		
(Loss)/Profit attributable to ordinary equity holders of the parent, used in the basic (loss)/earnings per share calculation	(1,155)	6,426

	Number of shares For the six months ended June 30,	
	2026	**2025**
Shares		
Weighted average number of ordinary shares outstanding during the period used in the basic (loss)/earnings per share calculation	468,343,092	468,343,092

10. PROPERTY, PLANT AND EQUIPMENT

During the six months ended June 30, 2026, the Group acquired assets at a cost of US$843,000 (six months ended June 30, 2025: US$2,139,000).

During the six months ended June 30, 2026, depreciation for property, plant and equipment was US$1,619,000 (six months ended June 30, 2025: US$1,710,000).

During the six months ended June 30, 2026, gain from disposal of property, plant and equipment was US$98,000 (six months ended June 30, 2025: Nil).

11. TRADE RECEIVABLES

	June 30, 2026 *US$'000 (Unaudited)*	December 31, 2025 *US$'000 (Audited)*
Trade receivables		
Current	109,248	96,032
Non-current	32,772	37,344
Subtotal	142,020	133,376
Impairment		
Current	(4,328)	(3,445)
Non-current	(634)	(1,426)
Subtotal	(4,962)	(4,871)
Net carrying amount		
Current	104,920	92,587
Non-current	32,138	35,918
Total	137,058	128,505

An ageing analysis of the trade receivables as at the end of the reporting period, based on the due date and net off loss allowance, is as follows:

	June 30, 2026 *US$'000 (Unaudited)*	December 31, 2025 *US$'000 (Audited)*
Within 1 month	118,911	109,525
1 to 2 months	3,250	3,820
2 to 3 months	4,134	4,857
Over 3 months	10,763	10,303
Total	137,058	128,505

12. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of reporting period, based on the invoice date, is as follows:

	June 30, 2026 *US$'000* *(Unaudited)*	December 31, 2025 *US$'000* *(Audited)*
Within 1 month	8,099	7,461
1 to 2 months	6,408	8,227
2 to 3 months	6,114	6,690
Over 3 months	3,878	549
Total	24,499	22,927

13. CONTINGENT LIABILITIES

As at June 30, 2026, the Group did not have any significant contingent liabilities.

14. COMMITMENTS

(a) Capital commitments

The Group did not have any significant capital commitments as at the end of the reporting period.

(b) Other business agreement

On October 26, 2022, and December 15, 2022, respectively, Sisram Medical (Tianjin) Limited (復銳醫療科技(天津)有限公司) ("**Sisram Tianjin**"), a subsidiary of the Group, entered into a sublicense agreement and its amendments with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("**Fosun Industrial**"), a subsidiary of Fosun Pharma, pursuant to which Sisram Tianjin agreed to sublicense from Fosun Industrial the relevant know-hows and patents of Daxxify, so as to, among other things, import, use, sell or commercialize the Daxxify in Chinese mainland, Hong Kong and Macau Special Administrative Regions ("**S.A.R.**"). The Group may be obligated to make future royalty payments on future sales of specified products associated with its collaboration agreements. Payments under these agreements generally become due and payable upon achievement of such sales. When the achievement of these sales has been reached, the corresponding amounts are recognized in the financial statements.

15. EVENTS AFTER THE REPORTING PERIOD

There was no significant event that took place after the reporting period and up to the date of approval of the financial statements.

MANAGEMENT DISCUSSION AND ANALYSIS

1. BUSINESS REVIEW

Sisram Medical Ltd is rapidly emerging as a distinguished global provider of medical aesthetic solutions, backed by over 25 years of leadership in the energy-based device ("**EBD**") sector. Anchored by a legacy of innovation and clinical excellence, the Company has cultivated a synergistic ecosystem spanning energy-based devices, injectables, diagnostics and AI-powered skincare. With a deep-rooted commitment to research, development, and the application of advanced energy technologies, Sisram has introduced a series of groundbreaking solutions that continue to redefine the standards of medical aesthetics. Expanding that offering and leveraging a robust commercial infrastructure spanning 12 direct-sales subsidiaries, Sisram is uniquely positioned as a premier platform for incubating and commercializing next-generation innovations in medical aesthetics.

Driven by a vision to enhance quality of life worldwide, Sisram empowers practitioners to deliver safe, effective, and life-transforming treatments. Its clinically proven portfolio seamlessly integrates EBD platforms, advanced injectables, diagnostic systems and AI-assisted skincare, all designed to support an intelligent, personalized aesthetic journey across a spectrum of patient needs. Recognized for its achievements, Sisram's award-winning solutions are trusted by tens of thousands of leading aesthetic clinics globally, with millions of patients benefiting from its technologies every day, solidifying its position as a global leader in the medical aesthetics industry.

2. BUSINESS REVIEW OF FIRST HALF OF 2026

During the Reporting Period, Sisram's global sales and distribution network generated total revenue of US$171.4 million, a 3.6% increase compared with the same period of 2025. Notably, second-quarter 2026 revenue recorded a strong increase on both a year-on-year and a quarter-on-quarter basis, reflecting continued positive momentum in sequential performance.

By geography, revenue from international markets (excluding North America) increased by 16.7% year-on-year to US$127.0 million, underscoring the resilience of the Company's diversified geographic footprint. Asia Pacific ("**APAC**") remained the largest and fastest-growing market, with revenue up 19.1% year-on-year to US$78.4 million, driven by strong performance across Mainland China, Thailand, Japan, and Hong Kong SAR. Europe revenue grew 12.1% year-on-year to US$26.7 million, while the Middle East and Africa revenue rose 20.9% year-on-year to US$16.8 million. In North America, despite an overall decline, Canada recorded over 20.0% year-on-year growth, signaling a partial recovery for the region. To address the current market conditions in North America, the Company has proactively refined its business model, execution setup, and cost base accordingly.

By segment, revenue from medical aesthetics amounted to US$134.3 million, representing a decrease of 2.5% year-on-year, primarily due to weaker performance in North America. Excluding North America, medical aesthetics revenue in international markets increased by 7.2% year-on-year, reflecting sustained global demand for the Company's core product platforms. The injectables business continued to gain momentum as the Company's second growth engine, with revenue reaching US$22.2 million, up 54.2% year-on-year. This growth was primarily driven by the commercial launch of DAXXIFY in Mainland China and sustained strong demand for Profhilo in Thailand, collectively reinforcing the strategic importance and long-term growth potential of the injectable's portfolio.

Gross profit for the Reporting Period amounted to US$97.2 million, representing a 2.1% decrease year-on-year. The gross profit margin stood at 56.7%, reflecting a decline of 3.3 percentage points from 60.0% in the same period of 2025. This margin contraction was primarily driven by changes in geographic mix and unfavorable product mix.

Operating expenses increased by 8.5% year-on-year, primarily due to continued investment in the Company's injectable business in China, including commercial infrastructure, medical education, and promotional activities to support the DAXXIFY launch. Excluding this strategic investment, the operating expense ratio contracted year-on-year, underscoring the underlying cost discipline and sustained efficiency gains across the Company's core operations.

For the Reporting Period, the Group recorded a profit before tax of US$2.3 million and a net profit of US$1.1 million, down 80.8% and 88.3% year-on-year, respectively, largely due to the gross profit decline and the increase in operating expenses. Adjusted net profit was US$5.0 million, down 57.9% year-on-year, with adjusted net profit margin at 2.9% of revenue, a decrease of 4.3 percentage points.

Despite the near-term profit decline, the Company's underlying business fundamentals remain solid, supported by a robust financial position that provides ample resources to fund future growth, sustain operational resilience, and execute against strategic priorities.

- Core EBD platforms maintain global leadership — The Alma Harmony, Hybrid and Soprano product families continued to generate robust global demand. Notable launches included Soprano Titanium in Thailand and the introduction of "黑金牛奶光" (Black Gold Photofacial) in Mainland China, further strengthening the Company's position in premium energy-based devices.

- Injectables business accelerates as a second growth engine — The injectables segment continued to gain momentum as the Company's second growth pillar, driven by DAXXIFY's achievement of key commercialization milestones in Mainland China and Profhilo's sustained strong performance in Thailand, collectively reinforcing the portfolio's strategic importance and long-term growth potential.

- AI-powered ecosystem gains traction — Universkin by Alma demonstrated strong customer retention and repeat orders in pilot markets. The Company is preparing for a broader international rollout in the second half of 2026, advancing its integrated ecosystem of diagnostics, treatment, and personalized skincare.

- Major milestone in China localization — The Beijing manufacturing facility commenced operations in June 2026, producing the first locally made Alma Rejuve. This marks a significant step in strengthening local supply chain efficiency, delivery responsiveness, and product availability, while supporting long-term growth across APAC.

R&D

- R&D expenses[1] totaled US$6.7 million, representing a 17.0% year-on-year decrease.

During the Reporting Period, the Company:

o Strengthened its R&D leadership with the appointment of Mr. Eran Shor as Executive Vice President of R&D. Mr. Shor is an accomplished multidisciplinary medical device R&D executive with more than 20 years of experience leading complex development programs across robotics, neurostimulation, drug-device combination products, and therapeutic systems. Prior to joining the Company, he held senior R&D leadership positions at several medical technology companies, including NeuroDerm, GI-View, PerfAction and XACT Robotics, bringing extensive expertise in system integration, translational development and the commercialization of advanced medical technology platforms.

o Further optimized its internal R&D organization and governance framework, while enhancing resource allocation and cross-functional coordination. Ongoing efforts have been directed at prioritizing high-impact development programs and key product pipeline initiatives, with the objective of improving development efficiency and accelerating the advancement of strategically important projects.

[1] *Note:* A government subsidy of US$1.85 million was recognized during the Reporting Period; net R&D expenses after subsidy offset amounted to US$6.7 million for the Reporting Period.

Clinical Research, Intellectual Property and Product Clearance:

- On the clinical research front, a total of 24 clinical and preclinical studies have been conducted to date. Of these, nine studies are currently ongoing, 11 have been completed, and 4 new studies were initiated during the Reporting Period and are now in the data collection phase.

- On the intellectual property front, the Company continued to strengthen its intellectual property ("**IP**") portfolio throughout the Reporting Period. Two new patent applications relating to a novel ultrasound device were filed, and one patent relating to a laser applicator was granted. In addition, four trademarks were registered, and eight new trademark applications were filed.

- As a major step in strengthening IP management, the Company consolidated all patent-related activities under a single leading patent attorney firm, streamlining prosecution and portfolio oversight while achieving meaningful cost efficiencies. In addition, several new directions for future patent applications were identified and reviewed, laying the groundwork for continued filings in the periods ahead.

Sales and Marketing

Building on its 2025 momentum, Sisram continued to deliver revenue growth across international markets in the first half of 2026, supported by robust global demand for its core EBD. At the same time, the Injectables business has established itself as a strong second growth engine, fueled by the successful commercialization of DAXXIFY in Mainland China and resilient demand for Profhilo in Thailand. Complementing these core product lines, the Company's AI-powered diagnostic and skincare ecosystem has continued to gain traction in pilot markets. Growth was broad-based across all regions outside North America, led by APAC and the Middle East — the latter benefiting from a recovery from the geopolitical disruptions that weighed on sales in the first half of 2025. As a result, the Company's center of gravity has increasingly shifted toward APAC, which accounted for nearly half of total first-half sales.

Core EBD Platforms

During the first half of 2026, Sisram's EBD business built upon its 2025 achievements to deliver sustained growth across international markets, supported by strong traction across key product families and a deepening commercial presence, especially in the APAC region.

The Soprano product family delivered sustained strong performance throughout the Reporting Period, underpinned by the successful market introduction of Soprano Titanium in Thailand and consistent demand across the APAC region. Since its launch in Thailand in June 2026, Soprano Titanium has been well received by leading medical aesthetic clinics, further reinforcing Sisram's position in the premium energy-based device segment. Concurrently, the Hybrid family maintained its growth trajectory across international markets, driven by robust demand for its versatile multi-application functionality and the clinical advantages of combination-treatment protocols.

Alma Harmony, the flagship multi-application platform, recorded consistently strong global sales, reflecting continued market adoption and clinical confidence. This performance was further supported by the successful uptake of proprietary treatment protocols, notably Harmony Bio-Boost and Pixel Peel. Harmony Bio-Boost has gained international recognition as a premium skin-rejuvenation solution, while Pixel Peel — a gentle, low-downtime laser resurfacing treatment — has been successfully expanded into new geographic markets. As Alma's most award-winning platform to date, the Harmony family continues to reinforce its market leadership position within the aesthetic device industry.

Together, the Harmony, Hybrid, and Soprano families drove sustained growth in the EBD category outside North America, reflecting strong practitioner confidence in Sisram's core technology platforms and treatment protocols.

Injectables Business — The Second Growth Engine

Alongside the established success of its core EBD operations, Sisram's injectables business delivered strong double-digit growth during the period, extending its exceptional performance in 2025. The segment's expansion was driven primarily by the commercial rollout of DAXXIFY in Mainland China and the sustained strength of Profhilo in Thailand, further establishing injectables as the Company's second major growth engine and demonstrating Sisram's ability to create additional growth pillars beyond its traditional device business.

- *DAXXIFY Commercialization in Mainland China*

  DAXXIFY achieved significant commercial milestones in Mainland China, with commercialization progressing at a strong pace. The product has become a key driver of growth within the injectables category, supported by increasing clinic adoption, strong physician engagement, and expanding consumer awareness.

As of June 30, 2026, cumulative commercial product shipments to clinics surpassed 30,000 vials, and the product reached nearly 500 premium medical aesthetic clinics across 28 provinces, including major regional clinic groups and high-end standalone clinics. The rollout has been bolstered by strong partner engagement, establishing a solid foundation for sustained commercial growth and deeper market penetration.

- *Profhilo Momentum in Thailand*

  Riding on its exceptional performance in 2025, Profhilo maintained robust growth in Thailand, bolstered by high adoption rates among top-tier clinics and expert physicians, as well as steady consumer demand. This performance further elevated Sisram's brand influence in the injectables market and strengthened local industry cooperation. Leveraging Thailand's strong medical infrastructure, high local demand, and thriving medical tourism market, the Company will continue to reinforce the region's role as its strategic APAC hub. Key initiatives include expanding the customer base, upgrading medical training and after-sales support, and advancing combined treatment protocols to unlock deeper synergies between the EBD and injectables businesses.

- *Hallura Market Expansion*

  Following its successful market debut in Israel in 2025, Hallura — the Company's innovative, BDDE-free hyaluronic acid filler — continued its steady commercial growth. The product's adoption among aesthetic physicians increased, fueled by its high safety profile and innovative "click" chemistry technology. With this commercial validation, Sisram is preparing to expand Hallura's commercial footprint into additional strategic markets, as part of its broader glocalization strategy to deliver innovative injectable solutions to a wider audience.

  Together, DAXXIFY, Profhilo, and Hallura demonstrate Sisram's ability to identify differentiated products, establish strong strategic partnerships, and successfully execute commercialization strategies across diverse markets. The continued momentum of the injectables portfolio further strengthens the Company's position as a leading provider of comprehensive medical aesthetics solutions.

AI-Powered Ecosystem

The Company's personalized diagnostics device, Alma IQ, and its AI-enabled skincare system Universkin by Alma, continued to demonstrate encouraging traction in the pilot markets. This performance was underpinned by exceptional customer retention and repeat-order levels that exceeded industry benchmarks. Featured in Glamour's Beauty Innovator 2026, Alma IQ was awarded Best Use of AI for Skin, recognizing its precision-driven, personalized approach to skin analysis. Notably, Universkin by Alma sustained robust momentum in the United States despite broader market softness. Building on this success, the Company has launched in the DACH markets (Germany, Austria and Switzerland), with further rollouts scheduled for the second half of the year.

Brand Building and Market Positioning

With a focus on strengthening business relationships, enhancing brand perception, and reinforcing its leadership position, the Company held its annual Global Alma Academy in Lisbon, Portugal. Now in its ninth year, the flagship event delivered Alma's strongest brand-building and revenue-generation results to date. Recognized as a leading professional academy in the aesthetic industry, it continues to play a strategic role in supporting the Company's market positioning and long-term growth trajectory.

To further expand global brand exposure through leading aesthetic congresses, the Company participated in IMCAS Paris with a distinctive three-day professional and clinical program alongside a prominent exhibition presence, delivering its highest-ever level of congress-related brand visibility. The Company also reinforced its presence in the rapidly growing Asian market through its participation in IMCAS Bangkok, which achieved strong results and attracted a marked increase in attendance compared with the prior year. The event also reflected the growing strategic importance of APAC within Sisram's global business and provided a strong platform to engage physicians, distributors, and key opinion leaders across the region.

Business Development

Localization in China

In January 2026, Sisram entered into a memorandum of understanding with Sinmait Medical Technology (Beijing) Co., Ltd. (星邁泰科醫療科技(北京)有限公司) ("**Sinmait Medical**") regarding potential cooperation to establish a local manufacturing presence for the Company's energy-based medical devices in China. Please refer to the Company's announcement dated January 21, 2026.

In June 2026, the Company's manufacturing facility in Miyun, Beijing commenced operations, with the first locally produced Alma Rejuve, an EBD platform recognized in China for its anti-aging and skin rejuvenation applications, rolling off the production line. This milestone marked significant progress in advancing Sisram's localization strategy in China and the ongoing expansion of its global smart manufacturing network. The Beijing facility builds upon the Israeli manufacturing arm's field-validated production workflows, stringent quality-control protocols, and decades of R&D and manufacturing expertise, integrating these proven standards into its local operations. Its state-of-the-art production lines further adapt and enhance this foundation to support the continued upgrading of the Company's manufacturing capabilities in China. With the commencement of operations, Sisram's China localization strategy has entered a new phase of full commercial operation, strengthened localized production capabilities, supply efficiency, delivery responsiveness, product quality consistency, and after-sales support, while enhancing product availability in China and supporting the Company's long-term growth across APAC.

DAXXIFY Commercialization in Mainland China

In March 2026, in connection with the commercialization of DAXXIFY in Mainland China, the Company set the annual caps for the Royalty Payments payable by Sisram Medical (Tianjin) Limited (復銳醫療科技(天津)有限公司) ("**Sisram Tianjin**") to Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. under the Sublicense Agreement at an amount not exceeding US$11.2 million for each of the three years ending December 31, 2026, 2027 and 2028. Please refer to the Company's announcement dated March 12, 2026.

In May 2026, Sisram Medical HK Limited ("**Sisram HK**") entered into the New Supply Framework Agreement with Fosun Wanbang (Jiangsu) Health Development Co., Ltd. (復星萬邦(江蘇)健康發展有限公司) ("**Fosun Wanbang (Jiangsu)**") to renew the Existing Supply Framework Agreement in relation to the supply and purchase of DAXXIFY in Mainland China. Pursuant to the New Supply Framework Agreement, Sisram HK may supply DAXXIFY to Fosun Wanbang (Jiangsu), and Fosun Wanbang (Jiangsu) may purchase DAXXIFY from Sisram HK during the term of the agreement. The New Supply Framework Agreement and the proposed annual caps of the transactions contemplated thereunder were approved by the Independent Shareholders on August 3, 2026. Please refer to the Company's announcements dated May 22, 2026 and August 3, 2026 and the Company's circular dated June 24, 2026.

In July 2026, Sisram Tianjin entered into the New Sublicense Agreement and the New Promotional Services Agreements with Fosun Wanbang (Jiangsu), which superseded and replaced the Original Commercial Distribution Co-operation Agreement in its entirety. The new agreements separately govern the sublicense and promotional services arrangements between the parties, with the relevant maximum transaction amounts revised to reflect the actual commercialization schedule of DAXXIFY in Mainland China, the scale and timing of promotional activities, and the business arrangements among the parties. Please refer to the Company's announcement dated July 10, 2026.

Following its initial launch, DAXXIFY delivered encouraging commercial results in Mainland China during the Reporting Period. As of June 30, 2026, cumulative commercial product shipments to clinics surpassed 30,000 vials, and the product has reached nearly 500 premium medical aesthetic clinics across 28 provinces, including major regional clinic groups and high-end standalone clinics. As DAXXIFY transitions from initial customer acquisition to a broader phase of market adoption and repeat purchases, the Company expects its commercial momentum to accelerate further. Looking ahead to the second half of 2026, the Company will focus on reinforcing DAXXIFY's premium positioning, deepening penetration among high-quality clinics, developing benchmark sites to drive utilization and repeat purchases, and refining localized injection protocols to establish clinical standards tailored to the Chinese market.

Concurrently, post-marketing research for DAXXIFY in Mainland China continues to advance. Clinical studies and real-world evidence generation in Chinese patients are expected to commence in the second half of 2026, subject to ethics approval, to support the product's long-term clinical application in the market.

Other Corporate and Recent Development

In April 2026, a reorganization at the controlling shareholder level was completed, pursuant to which Ample Up Limited and Chindex Medical Limited, both indirect wholly-owned subsidiaries of Fosun Pharma, transferred their entire shareholding interests in the Company, representing in aggregate approximately 71.42% of the Company's total issued shares, to Fosun Pharma Industrial Pte. Ltd., another indirect wholly-owned subsidiary of Fosun Pharma. Following the completion of the reorganization, Fosun Pharma's indirect equity interest in the Company remained unchanged. Please refer to the Company's announcement dated April 22, 2026.

In July 2026, Sisram unveiled "黑金牛奶光" (Black Gold Photofacial) in Mainland China — a strategic addition to its energy-based device portfolio that strengthens the Company's foothold in the fast-growing skin rejuvenation segment. With a proven commercial network and deep-rooted physician education capabilities, Sisram is poised to accelerate clinical adoption and elevate its brand presence across China's premium medical aesthetics landscape.

In July 2026, Sisram introduced Titanium Prime in Hong Kong SAR, a novel combination treatment concept integrating Alma PrimeX and Soprano Titanium. The platform harnesses a Trio-Energy Synergy of laser, radiofrequency and ultrasound, together with the proprietary BTS2 Methodology, to target multiple tissue layers across a broad spectrum of aesthetic indications, including skin brightening, tightening, texture refinement, facial contouring, collagen stimulation, and sculpting. The launch expands the Company's portfolio of synergistic, multi-platform solutions and underscores its capability to combine established EBD technologies into differentiated offerings tailored to local market needs. This initiative further advances Sisram's strategic commitment to delivering integrated aesthetic solutions and deepening its presence across key APAC markets.

Operations

Throughout the Reporting Period, the Company sustained stable production at its Israeli facility, maintaining inventory levels sufficient to meet customer demand. Responding to evolving global demand, notably the accelerating shift toward multi-energy platforms, the Company rolled out a comprehensive capacity ramp-up initiative that expanded manufacturing capacity, streamlined planning and material management, and elevated quality performance. As a direct result, lead times for high-demand EBD products have been significantly reduced, strengthening the Company's capacity to serve both current and future market requirements.

Concurrently, the Company continues to evolve its global service framework, underscoring its commitment to best-in-class service and the continuous enhancement of product reliability. Ongoing efforts are directed at further compressing repair turnaround times and driving sustained improvements in service efficiency and profitability.

On the glocalization front, building on the memorandum of understanding signed with Sinmait Medical Technology (Beijing) in January 2026, the Company has made significant strides in establishing a local manufacturing presence for energy-based devices in China. In June 2026, the manufacturing facility in Miyun, Beijing commenced operations, with the first locally produced Alma Rejuve, an EBD platform recognized in China for its anti-aging and skin rejuvenation applications, rolling off the production line.

The Beijing facility builds upon the Israeli manufacturing arm's field-validated production workflows, stringent quality-control protocols, and decades of R&D and manufacturing expertise, integrating these proven standards into its local operations. Its state-of-the-art production lines further adapt and enhance this foundation to support the continued upgrading of the Company's manufacturing capabilities in China.

With the commencement of operations, Sisram's China localization strategy has entered a new phase of full commercial execution. The facility strengthens coordination across manufacturing, supply chain management, sales, and after-sales support, improving delivery responsiveness and product quality consistency, while enhancing product availability in China and supporting the Company's long-term growth across APAC. This initiative also positions the Company to expand its localized product portfolio and reinforce its competitive edge in the region.

In parallel, the Company has maintained disciplined cost management through ongoing efficiency initiatives and tight control over direct operating expenses. Prudent hiring practices and targeted expense controls have been instrumental in mitigating macro headwinds, while ensuring that the Company retains the financial and operational flexibility to invest in its strategic growth priorities.

Despite ongoing geopolitical tensions in the Middle East, the Company's production and operational activities in Israel, as well as those of its subsidiaries across key regions, have remained normal. The Company has implemented comprehensive contingency measures, including adjustments to production scheduling, logistics arrangements, and workforce deployment, to protect employee safety, ensure supply continuity, and minimize any potential disruption to customers and partners, underscoring its operational resilience and proactive risk management.

Information Systems and Digital

During the Reporting Period, the Company continued to strengthen, standardize, and digitalize its global information systems and business processes. Core enterprise platforms were enhanced to achieve deeper integration across sales, marketing, operations, supply chain, and customer support functions, reinforcing end-to-end operational connectivity and cross-functional alignment.

The global CRM environment was further enhanced, streamlining unified sales processes across direct sales organizations and enhancing data consistency, visibility, and operational efficiency. Concurrently, the Company accelerated digital tool adoption and system integrations to support global supply chain operations, improving demand planning and increasing transparency across manufacturing, logistics, and distribution.

In addition, investments in data infrastructure and analytics capabilities enabled more robust data-driven decision-making and enriched commercial and operational insights. Collectively, these initiatives are designed to underpin scalability, operational resilience, regulatory compliance, and long-term growth as the Company continues to expand its global footprint.

3. OUTLOOK FOR SECOND HALF OF 2026

Sisram enters the second half of 2026 with strengthened commercial traction and a clear strategic roadmap, supported by solid momentum achieved in the first half. The Company remains confident in delivering stronger revenue in the second half of 2026, underpinned by healthy year-on-year growth in new orders across both core EBD platforms and the rapidly expanding injectables portfolio. Prioritizing profitability recovery and cash conversion, management is sharpening its focus on operational efficiency. With a robust financial position, a diversified global footprint, and an unwavering commitment to operational excellence, Sisram is well-equipped to capitalize on the significant long-term opportunities within the rapidly evolving aesthetic market.

Key initiatives for the second half of 2026 include:

- **DAXXIFY Commercialization in China:** Advance the phased expansion by broadening channel and clinic coverage, developing benchmark clinics, tailoring local injection protocols, and driving increased utilization and repeat purchases.

- **China Integration and Synergy:** Accelerate sales of next-generation energy-based devices and deepen the integration of commercial, customer, medical education, supply chain across the Company's EBD and injectables businesses in China.

- **China Localization and Manufacturing Ramp-up:** Accelerate production at the Beijing facility, expand the localized product portfolio, and enhance delivery, logistics, and after-sales support for China and APAC.

- **North America Ecosystem Advancement:** Prioritize performance stabilization and profitability recovery in North America, roll out new energy-based devices and treatment protocols, and enhance execution and cost alignment to return the region to sustainable growth.

- **Expanding Ecosystem Offering:** Globally, strengthen EBD and injectables pipelines with new platforms and treatment concepts tailored to each market's distinct clinical, regulatory, and consumer dynamics; expand AI-powered skincare solutions into additional territories; and deepen cross-category synergies to capture greater global market share.

- **Strategic Investments, M&A and Business Development:** Actively pursue ecosystem-aligned investments, M&A, licensing, and partnerships to enhance R&D capabilities and portfolio depth.

4. FINANCIAL REVIEW

During the Reporting Period, the unaudited interim results and the summary of financial results are as follows:

A. Revenue

For the Reporting Period, the Group's revenue increased to US$171.4 million from US$165.5 million, representing an increase of 3.6% compared with the same period of 2025. This performance underscores the Group's resilience amid challenging conditions in North America, where elevated interest rates and subdued consumer spending weighed on the regional market. Excluding these headwinds, Sisram delivered a robust 16.7% year-on-year revenue increase in International Market.

Revenue by Main Product Segments

The Group generates revenue from the following revenue streams: (i) sales of goods; and (ii) services and others.

The following table sets forth Sisram's revenue breakdown by main product lines and their respective percentages of the total revenue for the six months ended June 30 in the years indicated:

	Six months ended June 30,				
	2026		**2025**		**YOY%**
	(US$ in thousands, except for percentages)				
Medical Aesthetics:	134,311	78.4%	137,695	83.2%	−2.5%
Sale of Goods	134,311		137,695		
Injectables:	22,173	12.9%	14,377	8.7%	54.2%
Sale of Goods	19,087		14,377		
Sales of Services	3,086		—		
Services and Others:	14,939	8.7%	13,404	8.1%	11.5%
Total	**171,423**	**100.0%**	**165,476**	**100.0%**	**3.6%**

The Medical Aesthetics segment remained the Group's predominant revenue contributor, accounting for 78.4% of total revenue during the Reporting Period. Revenue from this segment totaled US$134.3 million for the six months ended June 30, 2026, reflecting a 2.5% decrease from US$137.7 million in the same period of 2025. The decline was primarily attributable to softer performance in North America. Despite this, the segment's revenue continued to be anchored by its established core EBD platforms, including Soprano, Hybrid and Alma Harmony.

Revenue from the Injectables segment totaled US$22.2 million for the six months ended June 30, 2026, representing a 54.2% increase from US$14.4 million in the same period of 2025. This strong performance was primarily driven by the commercial launch of DAXXIFY in Mainland China, alongside sustained robust demand for Profhilo in Thailand.

Revenue from Services and Others amounted to US$14.9 million for the six months ended June 30, 2026, representing an increase of 11.5% compared with the same period of 2025.

Revenue by Geographic Segments

The following table sets forth Sisram's revenue by geographic segments for the six months ended June 30, 2026 in the years indicated (based on the location of its direct sales customers and distributors):

	Six months ended June 30,				
	2026		**2025**		**YOY%**
	(US$ in thousands, except for percentages)				
North America	44,389	25.9%	56,597	34.2%	(21.6)%
APAC	78,407	45.7%	65,825	39.8%	19.1%
Europe	26,708	15.6%	23,827	14.4%	12.1%
Middle East and Africa	16,817	9.8%	13,910	8.4%	20.9%
Latin America	5,102	3.0%	5,317	3.2%	(4.0)%
Total	**171,423**	**100.0%**	**165,476**	**100.0%**	**3.6%**

The overall revenue increase during the Reporting Period was primarily driven by growth across APAC markets and the commercial rollout of DAXXIFY in Mainland China.

Revenue from North America totaled US$44.4 million, a decrease of 21.6% from US$56.6 million in the same period of 2025. This decline reflects persistent market headwinds, including elevated interest rates and weakened consumer spending.

Revenue from APAC increased by 19.1% to US$78.4 million from US$65.8 million in the same period of 2025, driven by strong performance across Mainland China, Thailand, Japan, and Hong Kong SAR.

Revenue from Europe increased by 12.1% to US$26.7 million from US$23.8 million in the same period of 2025, driven by significant demand growth for new EBD platforms in the region.

Revenue from the Middle East and Africa increased by 20.9% to US$16.8 million from US$13.9 million in the same period of 2025. This growth was mainly attributable to the resilience demonstrated by the Israeli market.

Revenue from Latin America edged down by US$0.2 million to US$5.1 million from US$5.3 million in the same period of 2025, primarily reflecting a high prior-year base due to a major chain transaction recorded in 2025.

B. Cost of Sales

Cost of sales consists primarily of material, labor, and overhead costs. During the Reporting Period, the Group's cost of sales increased by 12.2% to US$74.2 million from US$66.1 million in the same period of 2025. This increase was primarily attributable to a shift in product mix toward core-professional and sophisticated offerings, which involve higher material costs given their advanced technical specifications.

C. Gross Profit and Gross Profit Margin

Gross profit decreased by 2.1% to US$97.2 million during the Reporting Period, compared with US$99.3 million in the same period of 2025. Accordingly, the gross profit margin contracted to 56.7% from 60.0%. This margin contraction was primarily driven by changes in geographic mix and unfavorable product mix.

D. Selling and Distribution Expenses

Selling and distribution expenses primarily consist of: (i) employee salaries and related costs within the selling and distribution teams; (ii) sales commissions to sales employees and independent agents; (iii) marketing expenses, including trade show participation and digital initiatives.

During the Reporting Period, selling and distribution expenses increased by 7.3% to US$67.9 million from US$63.2 million in the same period of 2025, driven primarily by strategic investments to support the commercialization and expansion of the injectables business in China.

E. Administrative Expenses

Administrative expenses primarily consist of: (i) amortization of intangible assets; (ii) salaries and related costs for Finance, IT, HR, and administration personnel; (iii) professional fees and administrative costs; (iv) fees related to the operation facilities; (v) IT and HR expenses; and (vi) other miscellaneous expenses.

During the Reporting Period, administrative expenses increased by 10.2% to US$18.8 million from US$17.0 million in the same period of 2025. The increase was largely driven by costs associated with the Group's go-to-direct expansion strategy and continued strategic spending on the injectables business.

F. R&D

Research and development expenses primarily consist of: (i) employee salaries and related costs for R&D personnel; (ii) costs of materials used in R&D activities; (iii) expenses related to clinical studies; and (iv) expenses related to regulatory compliance and registration of patents and trademarks. During the Reporting Period, the majority of such costs were expensed as incurred and were not capitalized.

During the Reporting Period, R&D expenses decreased by 17.0% to US$6.7 million from US$8.1 million in the same period of 2025. This decline was mainly attributable to the recognition of a US$1.85 million government subsidy. Excluding this benefit, underlying R&D investment increased by 6.0% compared with the same period of 2025.

G. Finance Costs

Finance costs consist mainly of (i) interest on bank loans and (ii) interest on lease liabilities. Finance costs increased to US$2.0 million from US$1.4 million in the same period of 2025.

H. Income Tax Expense

The Israeli corporate tax rate remained unchanged at 23.0% for both 2025 and 2026, with each Group entity taxed on its standalone results in accordance with local tax regulations.

During the Reporting Period, income tax expense decreased by 57.0% to US$1.2 million from US$2.8 million in the same period of 2025, primarily due to lower profitability among subsidiaries operating in higher-tax-rate jurisdictions.

Consequently, the Group's effective tax rate, calculated as income tax expense divided by profit before tax, increased to 53.4% for the Reporting Period, compared with 23.8% in the same period of 2025.

I. Profit for the Period

As a result of the foregoing factors, the Group's profit for the period decreased by 88.3% to US$1.1 million from US$9.0 million in the same period of 2025. The Group's net profit margin for the six months ended June 30, 2026 and 2025 was 0.6% and 5.4%, respectively.

J. Adjusted Net Profit and Adjusted Net Profit Margin

The Group calculates adjusted net profit by adjusting profit for the period by excluding the following items: (i) amortization of intangible assets related to M&A and other transactions; (ii) contingent consideration relating to acquisitions; (iii) one-time gains or losses from investments; and (iv) deferred tax liabilities arising from other intangible assets, primarily in connection with acquisitions. Adjusted net profit margin is derived by dividing adjusted net profit by revenue.

The Group presents this non-IFRS financial measure as it is used to evaluate financial performance by excluding items that management does not consider indicative of the Group's core operating performance.

The term "adjusted net profit" is not a measure defined under IFRS and has material limitations as an analytical tool, as it does not capture all items that affect reported profit for the period. Accordingly, it should not be considered in isolation or as a substitute for financial results prepared in accordance with IFRS. The following table reconciles adjusted net profit for the Reporting Period to the most directly comparable IFRS measure, which is profit for the period:

	Six months ended June 30,		
	2026	**2025**	**YOY%**
	US$'000	*US$'000*	
PROFIT FOR THE PERIOD	1,053	8,987	(88.3)%
Adjusted for:			
Amortization of other intangible assets arising from the Alma acquisitions	1,376	1,376	0.0%
Amortization of other intangible assets arising from the Nova acquisitions	165	172	(4.1)%
Amortization of other intangible assets arising from the Foshion acquisition	207	200	3.5%
Amortization of other intangible assets arising from Alma China	2,053	2,057	(0.2)%
Amortization of other intangible assets arising from Sisram China — REVANCE	2,416	—	N/A
Contingent consideration arising from acquisitions	(516)	—	N/A
One-time income from investment in Belkin	(283)	—	N/A
Deduct: deferred tax arising from other intangible assets	(1,426)	(820)	73.9%
Adjusted net profit	5,045	11,972	(57.9)%
Adjusted net profit margin	2.9%	7.2%	

5. DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

A. Treasury Policy

The Board aims to maintain effective control over the Group's treasury operations and endeavors to sustain adequate levels of cash and cash equivalents. The Group's functional currency is the U.S. Dollar, and the majority of sales proceeds are denominated in U.S. Dollars. Please refer to "Risk Management — Foreign Currency Exposure" for further details. The Group generally finances its operations through internally generated resources and bank loans.

To ensure financial resources are deployed in the most cost-effective and efficient manner, the Board considers various funding sources to address the Group's financial obligations and operational needs and periodically reviews the adequacy and effectiveness of its treasury functions.

B. Gearing Ratio

As of June 30, 2026, and December 31, 2025, the Group's cash and cash equivalents exceeded total debt. As such, no gearing ratio is presented.

C. Interest Coverage

During the Reporting Period, interest coverage, which is calculated as EBIT (Earnings Before Interest and Taxes) divided by finance costs, was 2.1 times, compared with 9.2 times in the same period of 2025. The decrease was primarily attributable to a significant decline in EBIT from US$13.2 million in the same period of 2025 to US$4.3 million during the Reporting Period.

D. Available Banking Facilities

As of June 30, 2026, Sisram obtained a fixed short-term loan facility from an Israeli bank in amount of US$43.6 million, of which US$30.8 million had been utilized.

E. Interest Rate

As of June 30, 2026, total fixed-rate interest-bearing bank and other borrowings amounted to US$36.1 million (as of December 31, 2025: US$10.8 million).

F. Maturity Structure of Outstanding Debts

The following table sets forth the maturity profile of outstanding debts as of June 30, 2026, and December 31, 2025.

	June 30, 2026			December 31, 2025		
	Effective interest rate (%)	Maturity	US'000	Effective interest rate (%)	Maturity	US'000
Current			36,113			10,788
Fixed short-term loan	SOFR+169 –200bp	2026	30,800	SOFR +200bp	2026	5,304
Other borrowings*	3.3	2027	5,313	3.3–4.1	2026	5,484

* *Other borrowings are mainly loan from the Group's related parties.*

The maturity of the Group's outstanding borrowings is within 1 year.

6. CASH FLOW

Sisram uses its cash primarily for its operating activities, payments of interest and principals of debts due, purchases and capital expenditures, and funding growth and expansion of its business.

The table below shows the Group's cash flows generated from (or used in) operating activities, investing activities, and financing activities for the Reporting Period and the corresponding period of 2025.

	Six months ended June 30,		
	2026	2025	YOY%
	US$'000	US$'000	
Net cash flows used in operating activities	(17,029)	(4,891)	248.2%
Net cash flows used in investing activities	(1,578)	(1,824)	(13.5)%
Net cash flows generated from/(used in) financing activities	21,964	(5,441)	(503.7)%
Net increase/(decrease) in cash and cash equivalents	3,357	(12,156)	(127.6)%
Cash and cash equivalents at the beginning of the period	70,826	70,102	1.0%
Effect of foreign exchange rate changes, net	2,941	2,160	36.2%
Cash and cash equivalents at the end of the period	77,124	60,106	28.3%
Cash and cash equivalents			
Pledged bank balances	144	148	(2.7)%
Cash and bank balance at the end of the period	77,268	60,254	28.2%

Net cash flows used in operating activities

During the Reporting Period, the net cash flows used in operating activities were US$17.0 million, which was primarily attributable to (i) the profit before tax of US$2.3 million; (ii) total adjustments for profit or loss items of US$11.1 million; and (iii) working capital adjustments of US$30.4 million (a net cash outflow).

Net cash flows used in investing activities

During the Reporting Period, the net cash flows used in investing activities were US$1.6 million, which was primarily attributable to investments in associates and purchases of plant and equipment and intangible assets, partially offset by interest received and proceeds from the disposal of plant and equipment.

Net cash flows generated from financing activities

During the Reporting Period, the net cash flows generated from financing activities were US$22.0 million, which was primarily attributable to (i) proceeds from new bank loans of US$620.8 million; (ii) repayment of bank loans of US$595.7 million; (iii) lease payments of US$4.7 million; (iv) interest payments of US$0.7 million; and (v) proceeds from settlement of foreign currency forward contracts of US$2.2 million. No dividends were paid to non-controlling interests during the Reporting Period.

7. CAPITAL COMMITMENTS AND CAPITAL EXPENDITURES

During the Reporting Period, the Group's capital expenditures amounted to US$0.8 million, which mainly consisted of purchases of plant and equipment and intangible assets.

As of June 30, 2026, the Group did not have any significant capital commitments.

8. CONTINGENT LIABILITIES

As of June 30, 2026, the Group did not have any material contingent liabilities.

9. MATERIAL ACQUISITION AND DISPOSAL

During the Reporting Period, the Group did not conduct any material acquisition or disposal.

10. SIGNIFICANT INVESTMENTS HELD AND FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save for those disclosed in this announcement, there were no other significant investments held as at June 30, 2026. The Group did not have other plans for material investments and capital assets.

11. RISK MANAGEMENT

The operation and development of the Group are not exposed to any material risk factors, but they will be impacted to a certain extent by several factors as illustrated below:

A. Macroeconomic risk

Deterioration of economic conditions worldwide or in specific markets resulting from economic cycles, tariffs, political or social unrest, armed conflicts, government measures in response to outbreaks of contagious diseases, or other events or conditions may adversely affect the Group's business performance. Such factors may reduce the availability of funds and customer demand and may have a material adverse effect on the Group's net sales, profitability, cash flow and financial position.

The Company makes efforts to expand its direct operations infrastructure and implement its glocalization strategy to mitigate the risk of economic downturns in specific regions. In addition, the Company maintains a cost control mechanism to enable it to adjust expenses in response to macroeconomic events negatively impacting revenue performance.

B. Foreign currency exposure

The functional currency of the Company is the U.S. Dollar and most of the sales proceeds are denominated in the U.S. Dollar. However, the Company also generates revenue globally in a few other currencies, particularly Euros, and incurs costs mostly in New Israeli Shekels. Furthermore, the functional currencies of certain subsidiaries are currencies other than the U.S. Dollar, including the Euros, the Indian Rupee, the New Israeli Shekels, the HK Dollar, the South Korean Won, the Australian Dollar and the Chinese RMB. As at the end of the Reporting Period, the assets and liabilities of these entities were translated into the U.S. Dollar at the exchange rates prevailing at the end of the Reporting Period and their statements of profit or loss were translated into the U.S. Dollar at the weighted average exchange rates for the period. As such, the Group's results of operations are sensitive to changes in foreign currency exchange rates.

The Company formally established a hedging management framework in 2014 and the hedging transactions are mainly managed by the Company's finance department. By analyzing the currency balance sheet and trends in the foreign exchange markets, the Company has entered into forward contracts from time to time to mitigate the adverse effects of exchange rate fluctuations.

C. Interest rate exposure

It is the Group's strategy to use debts with fixed and floating interest rates to manage its interest costs. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's debt obligations with floating interest rates.

D. Legal and compliance risk

The Company's business and operations may be affected by unexpected or uncertain application of a law or regulation, which may result in penalties and operation costs.

The Company has engaged legal advisers in different jurisdictions to provide legal advice and suggest prompt actions on any regulatory updates.

12. EMPLOYEES AND REMUNERATION POLICIES

The following table sets forth the number of employees by function as of June 30, 2026:

Function	Number of Employees
Operations	277
R&D	71
Sales & Marketing	540
General and Administration	155
Total	1,043

Employees' headcount as at the end of the Reporting Period decreased by 4 employees as compared with December 31, 2025.

The employees' remuneration includes basic salary and a performance-based bonus. The performance-based bonus is determined by reference to the performance appraisal of the employees of the Group. Through clearly locating position-oriented performance targets and formulating performance standards, the Company has managed to assess employees' performance in an objective manner. By materializing reward and penalty in the performance-related portion of the employee's remuneration, the Company is able to achieve the coexistence of incentives and restraints.

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2026.

EVENTS AFTER THE END OF THE REPORTING PERIOD

Save as disclosed in this announcement, no significant events have occurred since the end of the Reporting Period and up to the date of this announcement.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries have purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares).

During the Reporting Period and up to the date of this announcement, the Company did not hold any treasury shares as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

COMPLIANCE WITH CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions set forth in the Corporate Governance Code (the "**CG Code**") contained in Part 2 of Appendix C1 to the Listing Rules.

During the Reporting Period, the Company has complied with all applicable principles and code provisions of the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted Directors' and Chief Executive Officer's Dealing Policy which is no less exacting than the required standard pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding directors' securities transactions. Having made specific enquiries to all directors of the Company, all directors of the Company confirmed that they have fully complied with the relevant requirements set out in its own code of conduct during the Reporting Period.

AUDIT COMMITTEE

The Board has established the audit committee ("**Audit Committee**") with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal controls system of our Group, review and approve connected transactions and provide advice and comments to the Board. The Audit Committee comprises Mr. Heung Sang Addy FONG, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU, with Mr. Heung Sang Addy FONG (being our independent non-executive Director with appropriate professional qualifications) as the chairperson.

The Audit Committee has reviewed the unaudited interim financial statements of the Group for the six months ended June 30, 2026.

Save as disclosed in this announcement, during the Reporting Period, there were no other material changes in respect of the Company that needed to be disclosed under paragraph 46 of Appendix D2 to the Listing Rules.

PUBLICATION OF INTERIM RESULTS AND 2026 INTERIM REPORT

This results announcement is published on the website of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") at http://www.hkexnews.hk and on the website of the Company at http://www.sisram-medical.com. The 2026 interim report containing all the information required by the Listing Rules will be dispatched to the shareholders of the Company who requested printed copy and will be published on the websites of the Company and the Stock Exchange in due course.

APPRECIATION

The Group would like to express its appreciation to all the staff for their outstanding contribution towards the Group's development. The Board wishes to sincerely thank the management for their dedication and diligence, which are key factors for the Group to continue its success in future. Also, the Group wishes to extend its gratitude for the continued support from its shareholders, customers, and business partners. The Group will continue to deliver sustainable business development, so as to create more value for all of its shareholders.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, August 19, 2026

As at the date of this announcement, the Board of the Company comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*